BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cheng JW, Lv Y. New progress of non-surgical treatments for hepatocellular carcinoma. Med Oncol 2013;30:381. [PMID: 23292867 DOI: 10.1007/s12032-012-0381-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
Number Citing Articles
1 Han JB, Kong FW, Ding H, Zhang YF, Liu JM, Wei Q, Hu L, Zhao L, Xu CJ, Yi YX. Hepatectomy combined with microwave ablation of the spleen for treatment of hepatocellular carcinoma complicated with splenomegaly: A retrospective study. Mol Clin Oncol 2017;6:204-8. [PMID: 28357095 DOI: 10.3892/mco.2016.1111] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
2 Fu J, Zhang JY, Wang FS. Tamibarotene: a new hope for therapeutic efficacy in hepatocellular carcinoma patients. Hepatol Int 2014;8:1-3. [PMID: 26202399 DOI: 10.1007/s12072-013-9493-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
3 Dong Z, Yao M, Wang L, Yan X, Gu X, Shi Y, Yao N, Qiu L, Wu W, Yao D. Abnormal expression of insulin-like growth factor-I receptor in hepatoma tissue and its inhibition to promote apoptosis of tumor cells. Tumour Biol. 2013;34:3397-3405. [PMID: 23797814 DOI: 10.1007/s13277-013-0912-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
4 Chen R, Sain NM, Harlow KT, Chen YJ, Shires PK, Heller R, Beebe SJ. A protective effect after clearance of orthotopic rat hepatocellular carcinoma by nanosecond pulsed electric fields. Eur J Cancer. 2014;50:2705-2713. [PMID: 25081978 DOI: 10.1016/j.ejca.2014.07.006] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 5.8] [Reference Citation Analysis]
5 Wang M. Comparison of prognostic value of three objective nutritional indicators in patients with hepatocellular carcinoma before radical resection. Shijie Huaren Xiaohua Zazhi 2019; 27(20): 1263-1270 [DOI: 10.11569/wcjd.v27.i20.1263] [Reference Citation Analysis]
6 Yimingjiang M, Tuergan T, Chen X, Wen H, Shao Y, Zhang R, Aihaiti K, Xue J, Aji T, Zhang W. Comparative Analysis of Immunoactivation by Nanosecond Pulsed Electric Fields and PD-1 Blockade in Murine Hepatocellular Carcinoma. Anal Cell Pathol (Amst) 2020;2020:9582731. [PMID: 32802733 DOI: 10.1155/2020/9582731] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Zhou ZF, Peng F, Li JY, Ye YB. Intratumoral IL-12 Gene Therapy Inhibits Tumor Growth In A HCC-Hu-PBL-NOD/SCID Murine Model. Onco Targets Ther 2019;12:7773-84. [PMID: 31571927 DOI: 10.2147/OTT.S222097] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Xu H, He C, Liu Y, Jiang J, Ma T. Novel therapeutic modalities and drug delivery - erlotinib liposomes modified with galactosylated lipid: in vitro and in vivo investigations. Artif Cells Nanomed Biotechnol 2018;46:1902-7. [PMID: 29081246 DOI: 10.1080/21691401.2017.1396222] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
9 Dai T, Zhang D, Cai M, Wang C, Wu Z, Ying Z, Wu J, Li M, Xie D, Li J. Golgi phosphoprotein 3 (GOLPH3) promotes hepatocellular carcinoma cell aggressiveness by activating the NF-κB pathway. J Pathol. 2015;235:490-501. [PMID: 25385148 DOI: 10.1002/path.4479] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 4.4] [Reference Citation Analysis]
10 Osaki Y, Nishikawa H. Treatment for hepatocellular carcinoma in Japan over the last three decades: Our experience and published work review. Hepatol Res 2015;45:59-74. [PMID: 24965914 DOI: 10.1111/hepr.12378] [Cited by in Crossref: 52] [Cited by in F6Publishing: 56] [Article Influence: 6.5] [Reference Citation Analysis]
11 Cheng J, Zhao P, Liu J, Liu X, Wu X. Preoperative aspartate aminotransferase-to-platelet ratio index (APRI) is a predictor on postoperative outcomes of hepatocellular carcinoma. Medicine (Baltimore) 2016;95:e5486. [PMID: 27902606 DOI: 10.1097/MD.0000000000005486] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
12 Shi J, Keller JM, Zhang J, Keller ET. A review on the diagnosis and treatment of hepatocellular carcinoma with a focus on the role of Wnts and the dickkopf family of Wnt inhibitors. J Hepatocell Carcinoma 2014;1:1-7. [PMID: 27508171 DOI: 10.2147/JHC.S44537] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
13 Park SH, Phuc NM, Lee J, Wu Z, Kim J, Kim H, Kim ND, Lee T, Song KS, Liu KH. Identification of acetylshikonin as the novel CYP2J2 inhibitor with anti-cancer activity in HepG2 cells. Phytomedicine 2017;24:134-40. [PMID: 28160853 DOI: 10.1016/j.phymed.2016.12.001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
14 Solorio L, Wu H, Hernandez C, Gangolli M, Exner AA. Ultrasound-guided intratumoral delivery of doxorubicin from in situ forming implants in a hepatocellular carcinoma model. Ther Deliv 2016;7:201-12. [PMID: 27010983 DOI: 10.4155/tde-2015-0008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
15 Zhang J, Zong Y, Xu GZ, Xing K. Erlotinib for advanced hepatocellular carcinoma. A systematic review of phase II/III clinical trials. Saudi Med J 2016;37:1184-90. [PMID: 27761555 DOI: 10.15537/smj.2016.11.16267] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
16 Gozzi GJ, Pires Ado R, Valdameri G, Rocha ME, Martinez GR, Noleto GR, Acco A, Alves de Souza CE, Echevarria A, Moretto Dos Reis C, Di Pietro A, Suter Correia Cadena SM. Selective Cytotoxicity of 1,3,4-Thiadiazolium Mesoionic Derivatives on Hepatocarcinoma Cells (HepG2). PLoS One 2015;10:e0130046. [PMID: 26083249 DOI: 10.1371/journal.pone.0130046] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
17 Liu H, Wei Q, Wang J, Huang X, Li C, Zheng Q, Cao J, Jia Z. DNA Polymerases as targets for gene therapy of hepatocellular carcinoma. BMC Cancer 2015;15:325. [PMID: 25924900 DOI: 10.1186/s12885-015-1339-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
18 Yao M, Wang L, Yang J, Yan X, Cai Y, Yao D. IGF-I receptor as an emerging potential molecular-targeted for hepatocellular carcinoma in vitro and in vivo. Tumor Biol 2016;37:14677-86. [DOI: 10.1007/s13277-016-5296-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
19 Chun S, Nam K, Lee K. Proton Beam Induces P53-mediated Cell Cycle Arrest in HepG2 Hepatocellular Carcinoma Cells. Biotechnol Bioproc E 2020;25:141-8. [DOI: 10.1007/s12257-019-0390-1] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]